Study type: In vivo/preclinical · Status: Evidence verified by machine against declared source
Myeloid cell-derived LL-37 promotes lung cancer growth by activating Wnt/β-catenin signaling.
Theranostics · 2019
Study scale: We compared the expression levels of LL-37 in 45 adjacent normal lung tissues and 86 NSCLC tissues (i.e., 47 adenocarcinomas and 39 squamous cell carcinomas) through immunohistochemistry.
Abstract only: Open source record
Product or molecular entity relationships
- LL-37: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Public plain-language summary
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Methods: The expression of LL-37 in the tissues and sera of patients with non-small cell lung cancer was determined through immunohistological, immunofluorescence analysis, and enzyme-linked immunosorbent assay.
Study design
The animal model of wild-type and Cramp knockout mice was employed to evaluate the tumorigenic effect of LL-37 in non-small cell lung cancer.
Participants or experimental system
In addition, LL-37 is involved in the regulation of tumor cell growth.
Study scale
We compared the expression levels of LL-37 in 45 adjacent normal lung tissues and 86 NSCLC tissues (i.e., 47 adenocarcinomas and 39 squamous cell carcinomas) through immunohistochemistry.
Intervention or exposure
The mechanism of LL-37 involving in the promotion of lung tumor growth was evaluated via microarray analyses, recombinant protein treatment approaches in vitro, tumor immunohistochemical assays, and intervention studies in vivo.
Comparator
The specificity of RT-PCR was controlled using 'no reverse transcription' controls and melting curve analysis.
Outcomes examined
Moreover, its expression level correlated with poor clinical outcome.
Key findings
Results: LL-37 produced by myeloid cells was frequently upregulated in primary human lung cancer tissues.
Limitations and uncertainty
Additionally, contrary to previous reports for other carcinomas 26, 27, LL-37 was mostly restricted to tumor-infiltrating immune cells (i.e., macrophages and neutrophils) with limited or no expression in tumor cells per se.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.